neostigmine and Acute Edematous Pancreatitis studies

Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.

Research Excerpts

Excerpt	Relevance	Reference
"This trial is a randomized, placebo-controlled, double-blinded, mono-centric trial that will test the hypothesis that neostigmine can improve gastrointestinal motility in patients with severe acute pancreatitis."	9.69	Efficacy and safety of neostigmine on treating gastrointestinal dysmotility in severe acute pancreatitis patients: study protocol for a randomized controlled trial. ( Du, T; Sheng, Y; Sun, H; Zhu, H, 2023)
"Intra-abdominal hypertension (IAH) in acute pancreatitis (AP) is associated with deterioration in organ function."	7.11	Randomized controlled trial: neostigmine for intra-abdominal hypertension in acute pancreatitis. ( Cai, W; Chen, P; He, W; Huang, W; Huang, X; Ke, H; Lei, Y; Liu, P; Lu, N; Sun, X; Sutton, R; Wu, Y; Xia, L; Zeng, H; Zhu, Y, 2022)
"This trial is a randomized, placebo-controlled, double-blinded, mono-centric trial that will test the hypothesis that neostigmine can improve gastrointestinal motility in patients with severe acute pancreatitis."	5.69	Efficacy and safety of neostigmine on treating gastrointestinal dysmotility in severe acute pancreatitis patients: study protocol for a randomized controlled trial. ( Du, T; Sheng, Y; Sun, H; Zhu, H, 2023)
"To determine the effect of intramuscular administration of Neostigmine® on the visualization of the pancreatic duct on magnetic resonance cholangiopancreatography in patients with recurrent acute pancreatitis or abdominal pain."	4.12	Neostigmine® Improves Pancreatic Duct Visualization in Magnetic Resonance Cholangiopancreatography and Could Be a Cheap Alternative for Secretin. ( Araya, F; Berger, Z; Cárdenas, G; Simian, D; Toledo, PF, 2022)
"Intra-abdominal hypertension (IAH) in acute pancreatitis (AP) is associated with deterioration in organ function."	3.11	Randomized controlled trial: neostigmine for intra-abdominal hypertension in acute pancreatitis. ( Cai, W; Chen, P; He, W; Huang, W; Huang, X; Ke, H; Lei, Y; Liu, P; Lu, N; Sun, X; Sutton, R; Wu, Y; Xia, L; Zeng, H; Zhu, Y, 2022)
"Ampullary stenosis was confirmed in all patients who subsequently underwent sphincteroplasty."	1.26	Duodenoscopy and endoscopic pancreatography in patients with postive morphine prostigmine tests. ( Capobianco, AG; Frager, SH; Gregg, JA; McCartney, AJ; Milano, AF; Santoro, BT; Taddeo, AE, 1977)

Research

Studies (23)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Days in Hospital

Timeframe	Studies, this research(%)	All Research%
pre-1990	18 (78.26)	18.7374
1990's	1 (4.35)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	4 (17.39)	2.80

Authors	Studies
He, W	1
Chen, P	1
Lei, Y	1
Xia, L	1
Liu, P	1
Zhu, Y	2
Zeng, H	1
Wu, Y	1
Ke, H	1
Huang, X	1
Cai, W	1
Sun, X	1
Huang, W	1
Sutton, R	1
Lu, N	1
Toledo, PF	1
Cárdenas, G	1
Berger, Z	1
Simian, D	1
Araya, F	1
Sun, H	1
Sheng, Y	1
Du, T	1
Zhu, H	1
He, K	1
Yan, X	1
Yang, Z	1
Zhang, Y	1
Shu, H	1
Wu, D	1
BONNET, J	1
DEKKER, WA	1
STERKEL, RJ	1
KNIGHT, WA	3
DIMENSHTEIN, IB	1
MUETHER, RO	1
SOMMER, AJ	1
Litvinov, VF	1
Potolochnyĭ, PL	1
Tsimmerman, IaS	1
Zueva, ED	1
Danielian, MA	1
Grigorian, EG	1
Gregg, JA	1
Taddeo, AE	1
Milano, AF	1
McCartney, AJ	1
Santoro, BT	1
Frager, SH	1
Capobianco, AG	1
Riccardi, VM	1
Shih, VE	1
Holmes, LB	1
Nardi, GL	3
Buntain, WL	1
Buonocore, E	1
Royal, SA	1
Sedasheva, IaE	1
Gullick, HD	1
Leibowitz, I	1
Geller, LI	1
Petrenko, VF	1
Romanets, VA	1
Kazimirchuk, AP	1
Brkić, D	1
Glisić, L	1
Subotić, Z	1
Glisić, Lj	1
Acosta, JM	1
Sterkel, RL	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Curative Effect and Security of Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension[NCT02543658]	Phase 2	80 participants (Actual)	Interventional	2015-09-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Days in hospital within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months

Days in ICU

Intervention	days (Median)
Neostigmine	20
Conservative Treatment	19

Days in ICU within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months

Death of 90 Days

Intervention	days (Median)
Neostigmine	12
Conservative Treatment	12

Death during from randomization to 90 days after onset. (NCT02543658)
Timeframe: From randomization to 90 days after onset.

Medical Expenses

Intervention	Participants (Count of Participants)
Neostigmine	10
Conservative Treatment	11

Medical expenses within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months

New-onset Abdominal Compartment Syndrom

Intervention	thousand(RMB) (Median)
Neostigmine	95.3
Conservative Treatment	102.3

Abdominal compartment syndrome is defined as a sustained IAP>20 mmHg (with or without an APP<60 mmHg) that is associated with new organ dysfunction/failure (NCT02543658)
Timeframe: From randomization to discharge or death, assessed up to 4 weeks

New-onset Organ Failure

Intervention	Participants (Count of Participants)
Neostigmine	2
Conservative Treatment	4

Incidence of organ failure from randomization to discharge or death, assessed up to 3 months (NCT02543658)
Timeframe: From randomization to discharge or death, assessed up to 3 months

Number of Participants With Adverse Effects on the Cardiovascular System

Intervention	Participants (Count of Participants)
Neostigmine	12
Conservative Treatment	16

Due to that neostigmine has an inhibitory effect on the cardiovascular system, new-onset cardiovascular failure after grouping is considered as a possible adverse event related to neostigmine.Cardiovascular failure was defined as circulatory systolic blood pressure <90 mm Hg, despite adequate fluid resuscitation, or need for inotropic catecholamine support (NCT02543658)
Timeframe: From randomization to 7 days

Number of Participants With Deterioration of IAH

Intervention	Participants (Count of Participants)
Neostigmine	8
Conservative Treatment	4

IAP rebound ≥ 5mmHg or increase ≥ 20mmHg within 1-7 days after grouping (NCT02543658)
Timeframe: From randomization to 7 days

Timing of Enteral Nutrition

Intervention	Participants (Count of Participants)
Neostigmine	4
Conservative Treatment	8

From date of randomization to enteral nutrition, assessed up to 30 days (NCT02543658)
Timeframe: Start time of enteral nutrition after randomization, assessed up to 30 days

Percent Change of IAP After Treatment

Intervention	days (Median)
Neostigmine	3
Conservative Treatment	4

Monitor the intra-abdominal pressure within 1 to 7 days after randomization, and calculate the percent change compared with that before randomization (NCT02543658)
Timeframe: From randomization to 7 days after treatment,Measured IAP every 6 hours

The Change of Stool Volume at 1-7 Days After Randomization

Intervention	percent change of IAP (Median)
	percent change of IAP at 24 hours	percent change of IAP at 7 days
Conservative Treatment	-5.4	-20.0
Neostigmine	-18.7	-27.2

After randomization, the change of stool volume (ML) was calculated every 24 hours.For example, the amount of stool volume decreased or increased in 24 hours after grouping compared to before grouping. (NCT02543658)
Timeframe: From randomization to 7 days

Intervention	ml/day (Median)
	The change of stool volume at 24 hours	The change of stool volume at 7th day
Conservative Treatment	60	370
Neostigmine	870	1025

Article	Year
Randomized controlled trial: neostigmine for intra-abdominal hypertension in acute pancreatitis. Critical care (London, England), 2022, 03-03, Volume: 26, Issue:1 Topics: Acute Disease; Humans; Intra-Abdominal Hypertension; Neostigmine; Pancreatitis	2022
Efficacy and safety of neostigmine on treating gastrointestinal dysmotility in severe acute pancreatitis patients: study protocol for a randomized controlled trial. Trials, 2023, Feb-06, Volume: 24, Issue:1 Topics: Acute Disease; Enteral Nutrition; Humans; Infant, Newborn; Intestinal Pseudo-Obstruction; Neostigmin	2023

Article	Year
Neostigmine® Improves Pancreatic Duct Visualization in Magnetic Resonance Cholangiopancreatography and Could Be a Cheap Alternative for Secretin. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2022, Volume: 33, Issue:8 Topics: Abdominal Pain; Acute Disease; Adolescent; Adult; Cholangiopancreatography, Endoscopic Retrograde; C	2022
Neostigmine for the treatment of acute pancreatitis: a protocol for a systematic review and meta-analysis. BMJ open, 2023, 03-23, Volume: 13, Issue:3 Topics: Acute Disease; Humans; Meta-Analysis as Topic; Neostigmine; Pancreatitis; Research Design; Systemati	2023
The diagnosis of chronic pancreatitis. Archivum chirurgicum Neerlandicum, 1954, Volume: 6, Issue:1 Topics: Humans; Neostigmine; Pancreatitis; Pancreatitis, Chronic	1954
THE VALUE OF A PROVACATIVE SERUM ENZYME TEST IN "PANCREATIC DYSPEPSIA". Southern medical journal, 1965, Volume: 58 Topics: Amylases; Blood; Clinical Enzyme Tests; Dyspepsia; Glycoside Hydrolases; Humans; Morphine; Neostigmi	1965
[CLINICAL IMPORTANCE OF THE PROSERIN TEST IN CHRONIC PANCREATITIS, CHRONIC CHOLECYSTITIS AND OBSTRUCTIVE JAUNDICE]. Terapevticheskii arkhiv, 1965, Volume: 37 Topics: Cholecystitis; Humans; Jaundice; Jaundice, Obstructive; Neostigmine; Pancreatitis; Pancreatitis, Chr	1965
Chronic recurrent pancreatitis; serial serum diastase levels following prostigmine stimulation. Gastroenterology, 1949, Volume: 12, Issue:1 Topics: Amylases; Humans; Neostigmine; Pancreatitis; Pancreatitis, Chronic	1949
[Diagnostic value of the morphine-neostigmine test in chronic pancreatitis]. Vestnik khirurgii imeni I. I. Grekova, 1981, Volume: 126, Issue:6 Topics: Adult; Aged; Chronic Disease; Humans; Middle Aged; Morphine; Neostigmine; Pancreatitis	1981
[Diagnostic evaluation of tubeless methods in the study of external secretions of the pancreas]. Klinicheskaia laboratornaia diagnostika, 1997, Issue:9 Topics: Adult; Amino Acids; Amylases; Cholecystitis; Chronic Disease; Creatinine; Diagnosis, Differential; D	1997
[Evaluation of different methods of measurement of the level of diastase in urine for determination of the degree of inflammatory changes in the pancreas]. Laboratornoe delo, 1976, Issue:3 Topics: Acute Disease; Adult; Amylases; Chronic Disease; Clinical Enzyme Tests; Evaluation Studies as Topic;	1976
Duodenoscopy and endoscopic pancreatography in patients with postive morphine prostigmine tests. American journal of surgery, 1977, Volume: 134, Issue:3 Topics: Adolescent; Adult; Biliary Tract Diseases; Cholangiography; Cholecystectomy; Chronic Disease; Cicatr	1977
Hereditary pancreatitis. Nonspecificity of aminoaciduria and diagnosis of occult disease. Archives of internal medicine, 1975, Volume: 135, Issue:6 Topics: Adult; Amino Acids; Female; Genes, Dominant; Humans; Infant; Male; Middle Aged; Morphine; Neostigmin	1975
Beneficial use of an evocative test in chronic relapsing pancreatitis in children. American journal of surgery, 1986, Volume: 152, Issue:6 Topics: Abdomen; Adolescent; Amylases; Child; Child, Preschool; Chronic Disease; Female; Humans; Male; Morph	1986
[Determining urinary lipase after a morphine-proserine loading for the differential diagnosis of several diseases of the gastrointestinal tract]. Laboratornoe delo, 1972, Volume: 4 Topics: Chronic Disease; Diagnosis, Differential; Gastrointestinal Diseases; Humans; Lipase; Morphine; Neost	1972
Relation of the magnitude of blood enzyme elevation to severity of exocrine pancreatic disease. The American journal of digestive diseases, 1973, Volume: 18, Issue:5 Topics: Acute Disease; Adult; Aged; Amylases; Cholecystokinin; Chronic Disease; Clinical Enzyme Tests; Femal	1973
Prolonged paresis following the administration of gallamine triethiodide (Flaxedil) to a patient with acute pancreatitis. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1973, Jun-16, Volume: 47, Issue:23 Topics: Acute Disease; Acute Kidney Injury; Anesthesia, General; Atropine; Gallamine Triethiodide; Humans; M	1973
Papillitis and stenosis of the sphincter of Oddi. The Surgical clinics of North America, 1973, Volume: 53, Issue:5 Topics: Ampulla of Vater; Biliary Tract Diseases; Clinical Enzyme Tests; Common Bile Duct; Humans; Morphine;	1973
[Pressure in the duodenum and effect on it of certain preparations in patients with chronic pancreatitis]. Klinicheskaia meditsina, 1973, Volume: 51, Issue:7 Topics: Atropine; Bis-Trimethylammonium Compounds; Chronic Disease; Duodenum; Humans; Intestinal Secretions;	1973
[Secretin and pancreozymin in diagnosis of pancreatitis]. Medicinski glasnik, 1968, Volume: 22, Issue:7 Topics: Aged; Cholecystokinin; Humans; Methods; Middle Aged; Neostigmine; Pancreatitis; Secretin	1968
[Prostigmine-pancreozymin test in diagnosis of pancreatic diseases]. Srpski arhiv za celokupno lekarstvo, 1969, Volume: 97, Issue:4 Topics: Acute Disease; Cholecystokinin; Chronic Disease; Humans; Neostigmine; Pancreatic Neoplasms; Pancreat	1969
Papillitis as a cause of pancreatitis and abdominal pain: role of evocative test, operative pancreatography and histologic evaluation. Annals of surgery, 1966, Volume: 164, Issue:4 Topics: Abdomen, Acute; Ampulla of Vater; Biliary Tract Diseases; Biopsy; Humans; Morphine; Neostigmine; Pan	1966
Effect of pentaerythritol tetranitrate (PETN) on the positive prostigmin-morphine diastase response. The American journal of digestive diseases, 1966, Volume: 11, Issue:11 Topics: Adult; Biliary Tract Diseases; Clinical Enzyme Tests; Female; Humans; Male; Middle Aged; Morphine; N	1966

neostigmine and Acute Edematous Pancreatitis